Get Updates

Voices of Hope:
Real Stories from AL Amyloidosis Warriors

Discover the transformative journeys of individuals who have bravely navigated their treatment with our groundbreaking therapy. Hear firsthand how their lives have been changed and their futures reimagined.
Patient First

ACT EARLY. LIVE BETTER

Be Proactive in AL

Immix Biopharma’s ‘Be Proactive in AL’ initiative empowers patients and healthcare providers to recognize and address AL amyloidosis early. By enhancing awareness and promoting early diagnostic strategies, we aim to significantly improve patient outcomes and quality of life through timely interventions. Join us in transforming the approach to this challenging disease.

U.S. observed prevalence of AL Amyloidosis estimated to reach 38,563 patients by the end of 2026. No FDA approved treatments available for relapsed/refractory AL Amyloidosis

Due to its nonspecific symptoms, such as fatigue, weight loss, and swelling, the condition is often misdiagnosed or detected in later stages.

Without effective treatment, the median survival rate for AL patients with advanced cardiac involvement can be less than a year.

Our Patient First Approach

Revolutionizing Treatment
At the heart of our mission lies a steadfast commitment to patient welfare. Our innovative single-day CAR-T therapy, the first of its kind, is designed to minimize disruption in our patients’ lives while maximizing treatment effectiveness. By reducing hospital stays and side effects, we ensure a smoother, more comfortable recovery process, prioritizing your health and time.
What is AL Amyloidosis?

AL Amyloidosis is a rare but serious disease that occurs when an abnormal protein called amyloid builds up in your organs and tissues. These proteins are produced in the bone marrow and can accumulate in different parts of the body, including the heart, kidneys, liver, spleen, nervous system, and digestive tract. This buildup can interfere with the normal function of these organs and can lead to severe health complications if left untreated.

At Immix Biopharma, we are pioneering a new approach to treating AL Amyloidosis using CAR T-cell therapy. This innovative treatment harnesses your own immune system to fight the disease, offering a potential curative solution where traditional treatments have failed. Early results have shown promising results, providing new hope for patients who have exhausted other options.

Learn About Our Clinical Trial

ASH 2025 Data

Extraordinary Results in Clinical Trials

Unprecedented outcomes in one of medicine’s most challenging diseases. Our U.S. NEXICART-2 registrational trial is delivering results that are transforming the treatment landscape for relapsed/refractory AL amyloidosis.

Current Standard of Care

0%

Complete Response Rate
(Investigator’s Choice)

With NXC‑201

0%

Complete Response Rate

(NEXICART‑2, ASH 2025)
BREAKTHROUGH

"An early and deep hematologic response has been found to lead to significantly prolonged survival."

Vaishali Sanchorawala, M.D.

Professor of Hematology and Oncology
Director, Amyloidosis Center at Boston University School of Medicine

0/20

Patients

Normalized disease markers

0 Days

Median Time

To response

0%

Neurotoxicity

Across all patients

4-8x

Shorter CRS

vs. other BMCA CAR-Ts

View Clinical Results